Dr. Miles Cunningham, Founder and Chief Scientific Officer, will present on the development and capabilities of the company's lead product, the Intracerebral Microinjection Instrument.
Belmont, MA, May 14, 2015 (Newswire) - Atanse, Inc., a developer of advanced neurosurgical instruments, today announced that its Founder and Chief Scientific Officer, Dr. Miles Cunningham, will present at the World Stem Cells and Regenerative Medicine Congress in London on May 20-22, 2015. Dr. Cunningham will provide an introduction to his research relating to the Intracerebral Microinjection Instrument (IMI), a direct injection device designed for the intracerebral delivery of stem cells, viral vectors, and other restorative therapeutics. Through the utilization of radial microcannula technology, the IMI enables precise therapeutic delivery in three dimensions while minimizing brain tissue trauma. Dr. Cunningham will also provide an overview of how the IMI is successfully being utilized in clinical research settings for therapeutic stem cell delivery.
For more information about the World Stem Cells and Regenerative Medicine Conference, please visit terrapinn.com/conference/stem-cells.
About Dr. Miles Cunningham
Dr. Cunningham is the Director of the Laboratory for Neural Reconstruction at McLean Hospital and an Assistant Professor of Psychiatry at Harvard Medical School. He holds an M.D. from Harvard University and a Ph.D. from the Massachusetts Institute of Technology. Dr. Cunningham is the inventor of the IMI and founded Atanse in 2010 to commercialize it and other related neurosurgical technologies.
Atanse, Inc. enables the treatment of devastating neurological diseases through pioneering intracerebral therapeutic delivery technology. We strive to develop instruments that provide neurosurgeons with the highest possible accuracy and precision while minimizing associated trauma. For more information about Atanse, please visit atanse.com.
About the Intracerebral Microinjection Instrument (IMI)
The IMI is a minimally invasive therapeutic delivery device that provides neurosurgeons with improved control and precision, reduction in trauma and morbidity, and improved treatment efficacy. The device utilizes Atanse’s patented radial microcannula technology, which permits three-dimensional dissemination of therapeutic from a single penetration of brain tissue. The technology has been optimized for human applications through numerous preclinical studies in animal models at MIT and Harvard Medical School over the past decade. For more information about the IMI, please visit atanse.com/technology.
For further inquiries, please contact:
Adam Leonard, Director of Strategic Partnerships
1 (339) 225-9639